Core Insights - Clearmind Medicine Inc. has successfully completed treatment for all patients in the second cohort of its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Progress - The second cohort included six patients from leading clinical sites such as Johns Hopkins University and Tel Aviv Sourasky Medical Center, completing treatment as per protocol [2] - This milestone follows positive results from the first cohort, which indicated a favorable safety profile and preliminary efficacy, including reduced cravings and withdrawal symptoms [2][3] - The CEO of Clearmind Medicine expressed satisfaction with the progress and highlighted the strong interest in CMND-100 as a potential innovative therapy for AUD, a condition with significant unmet medical needs [3] Group 2: Company Overview - Clearmind is a clinical-stage psychedelic pharmaceutical biotech company focused on developing novel psychedelic-derived therapeutics to address widespread health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as necessary [5] - Clearmind's shares are traded on Nasdaq under the symbol "CMND" and on the Frankfurt Stock Exchange under "CWY0" [5]

Core Viewpoint - Clearmind Medicine Inc. has regained compliance with Nasdaq's minimum bid price requirement after its shares closed at $1.00 or greater for 10 consecutive business days, resolving a previous non-compliance issue [1][3]. Company Overview - Clearmind Medicine Inc. is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics aimed at addressing significant under-treated health issues, including alcohol use disorder [4]. - The company holds an intellectual property portfolio consisting of 19 patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property as opportunities arise [5]. Compliance Update - On December 4, 2025, Nasdaq notified the company of its non-compliance with the minimum bid price requirement due to its shares trading below $1.00 for over 30 consecutive business days [2]. - Following a period of compliance, Nasdaq confirmed on December 30, 2025, that the company's shares had met the minimum bid price requirement, thus closing the matter [3].

Core Insights - Clearmind Medicine Inc. has made significant progress in 2025, particularly in advancing its lead candidate, CMND-100, for the treatment of Alcohol Use Disorder (AUD) [1][2] Clinical Trial Progress - Clearmind advanced its multinational Phase I/IIa clinical trial for CMND-100, with site activations at prestigious institutions such as Yale School of Medicine and Johns Hopkins University [3] - The company successfully initiated first-in-human dosing, completed treatment and enrollment for the first cohort, and reported positive top-line safety and tolerability results with no serious adverse events [3] - Enrollment and dosing for the second cohort were completed, accelerating the path toward further data readouts [3] Independent Safety Endorsement - Clearmind received unanimous approval from the Data and Safety Monitoring Board (DSMB) to continue the Phase I/IIa clinical trial following an interim review, reinforcing CMND-100's favorable safety profile [4] Global Footprint Expansion - The company strengthened its intellectual property portfolio with multiple international patent filings and publications targeting various health indications, including weight loss, obesity, and mental health disorders [5] Leadership Commentary - The CEO of Clearmind highlighted 2025 as a pivotal year for the company, emphasizing its transition into a clinical-stage entity and commitment to delivering transformative treatments for addictions and mental health challenges [6] Intellectual Property Portfolio - Clearmind's intellectual portfolio consists of nineteen patent families, including 31 granted patents, with plans to seek additional patents as warranted [8]

Core Insights - Clearmind Medicine Inc. has successfully completed patient enrollment for the second cohort in its FDA-approved Phase I/IIa clinical trial for CMND-100, an oral drug candidate aimed at treating Alcohol Use Disorder (AUD) [1][4] - The first cohort showed promising safety and efficacy results, indicating a favorable safety profile and preliminary signs of reduced cravings and withdrawal symptoms [2][4] - The rapid enrollment of the second cohort underscores the commitment of collaborating clinical centers to advance innovative treatments for AUD, a condition with limited effective options affecting millions globally [3][4] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][5] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents and acquire more intellectual property [6] Clinical Trial Details - The multinational Phase I/IIa trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in patients with moderate to severe AUD, with dosing for the second cohort expected to start soon [4]

Core Insights - Clearmind Medicine Inc. has enrolled and dosed the first participant in its Phase I/IIa clinical trial for Alcohol Use Disorder (AUD) with its proprietary drug candidate CMND-100 at Hadassah-University Medical Center in Jerusalem, marking a significant milestone in the trial [1][2][3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address major under-treated health issues, including AUD [1][4] - The company aims to research and commercialize psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The trial at Hadassah-University Medical Center is led by Prof. Joseph Caraco and evaluates the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100 in AUD patients [2] - Recent positive results from the first cohort and a unanimous recommendation from the Data and Safety Monitoring Board support the continuation of the trial [2] Intellectual Property - Clearmind's intellectual portfolio includes nineteen patent families with 31 granted patents, and the company plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has commenced patient enrollment for its Phase I/IIa clinical trial of CMND-100 for Alcohol Use Disorder (AUD) at Tel Aviv Sourasky Medical Center, marking a significant milestone in the global study [1][2][4] - The trial aims to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of CMND-100, a non-hallucinogenic, oral MEAI-based compound, with initial results indicating excellent safety and adherence [3][4] - Clearmind's intellectual property portfolio includes nineteen patent families with 31 granted patents, and the company plans to pursue additional patents to enhance its portfolio [5] Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel neuroplastogen-derived therapeutics to address under-treated health issues, particularly AUD [1][4] - The company is committed to researching and commercializing psychedelic-based compounds as regulated medicines, foods, or supplements [4] Clinical Trial Details - The Phase I/IIa trial is being conducted at multiple prestigious sites, including Yale School of Medicine and Johns Hopkins University, in addition to TASMC [2] - The first completed cohort of the trial has shown no serious adverse events, indicating a positive safety profile for CMND-100 [3]

Core Insights - Clearmind Medicine Inc. has received a positive recommendation from its independent Data and Safety Monitoring Board (DSMB) to continue its Phase I/IIa clinical trial for CMND-100, a non-hallucinogenic neuroplastogen aimed at treating Alcohol Use Disorder (AUD) [1][2][3] Group 1: Clinical Trial Details - The ongoing multinational, multi-center trial is assessing the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - The DSMB's review highlighted a favorable safety profile with no serious adverse events reported and general good tolerability across all participants [6] Group 2: Company Statements and Future Outlook - The CEO of Clearmind expressed confidence in CMND-100's safety and therapeutic potential, indicating that the positive interim data positions the company to accelerate enrollment in the trial [3] - The DSMB was established in 2023 to ensure patient safety and data integrity throughout the trial, reflecting the company's commitment to ethical clinical development [3] Group 3: Company Background and Intellectual Property - Clearmind is focused on developing novel psychedelic-derived therapeutics to address significant health issues, including AUD, with the goal of commercializing these compounds as regulated medicines [4] - The company holds an intellectual property portfolio consisting of nineteen patent families, including 31 granted patents, and plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding the trial's reach and emphasizing the potential of this non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD) [1][2] Group 1: Clinical Trial Details - The multinational study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - Hadassah Medical Center was added as a clinical site for the ongoing trial, which was activated swiftly following final approval earlier in the month [2] Group 2: Early Findings - Top-line data from the first cohort of the clinical trial indicated a favorable safety profile, with no serious adverse events reported and high adherence to the dosing regimen [3] - These early findings support the ongoing evaluation of CMND-100 as a potential breakthrough therapy for AUD, a condition affecting millions globally [3] Group 3: Company Overview - Clearmind is a clinical-stage biotech company focused on developing novel psychedelic-derived therapeutics to address under-treated health issues, including AUD [4] - The company's intellectual portfolio includes nineteen patent families with 31 granted patents, and it plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has initiated its FDA-approved Phase I/IIa clinical trial for CMND-100 at Hadassah Medical Center, expanding the trial's reach and emphasizing the potential of this non-hallucinogenic MEAI-based oral drug candidate for treating Alcohol Use Disorder (AUD) [1][2] Group 1: Clinical Trial Details - The multinational study aims to evaluate the safety, tolerability, pharmacokinetic profile, and preliminary efficacy of CMND-100 in reducing alcohol cravings and consumption among individuals with moderate to severe AUD [2] - Hadassah Medical Center was added as a clinical site following final approval earlier in November 2025, indicating swift activation and commitment to the trial [2] Group 2: Early Findings - Top-line data from the first cohort of the clinical trial showed a favorable safety profile with no serious adverse events reported, indicating that the treatment was well-tolerated among participants [3] - High adherence to the dosing regimen and protocol requirements was observed, supporting the feasibility and patient acceptability of CMND-100 in a clinical setting [3] Group 3: Company Overview - Clearmind is focused on the discovery and development of novel psychedelic-derived therapeutics to address widespread health issues, including AUD [4] - The company holds an intellectual property portfolio consisting of nineteen patent families and 31 granted patents, with plans to seek additional patents as warranted [5]

Core Insights - Clearmind Medicine Inc. has filed a patent application in Israel for a combination therapy targeting depression, utilizing 5-methoxy-2-aminoindane (MEAI) and N-Acylethanolamines like Palmitoylethanolamide (PEA) [1][2] - The collaboration with Neurothera Labs Inc. aims to address the significant global issue of major depressive disorder, which affects over 280 million people and is a leading cause of disability [2] - The CEO of Clearmind emphasized the importance of this patent application as a milestone in developing innovative treatments for mental health conditions, highlighting the lag in treatment innovation for depression [3] Company Overview - Clearmind is a clinical-stage biotech company focused on developing psychedelic-derived therapeutics to address under-treated health issues, including alcohol use disorder [4] - The company has an extensive intellectual property portfolio, currently consisting of 19 patent families and 31 granted patents, with plans to seek additional patents as warranted [5] Research and Development - The new patent filing expands Clearmind's intellectual property related to MEAI and N-Acylethanolamines, targeting various conditions such as alcohol use disorder, cocaine addiction, obesity, and depression [3] - Preclinical data supports the efficacy of MEAI in reducing addictive behaviors while maintaining normal reward pathways [3]